Blackstone Inc
CNTX icon

Blackstone Inc’s Context Therapeutics CNTX Stock Holding History

Blackstone Inc’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,440,330
Closed -$3.59M – 428
2025
Q4 		$3.59M Hold
2,440,330
– – 0.01% 143
2025
Q3 		$2.36M Hold
2,440,330
– – 0.01% 129
2025
Q2 		$1.6M Hold
2,440,330
– – 0.01% 114
2025
Q1 		$1.49M Hold
2,440,330
– – 0.01% 117
2024
Q4 		$2.56M Hold
2,440,330
– – 0.01% 107
2024
Q3 		$4.78M Buy
2,440,330
+601,621
+33% +$1.33M 0.02% 96
2024
Q2 		$3.69M Buy
+1,838,709
New +$3.17M 0.02% 106

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Blackstone Inc's CNTX Position: Q1 2026 in Review

Blackstone Inc sold out of Context Therapeutics (CNTX) in Q1 2026, closing a stake of 2,440,330 shares — an estimated $3.59M sold.

Blackstone Inc first reported a position in CNTX in Q2 2024 and held it in 7 quarters. The position peaked at $4.78M in Q3 2024. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • Blackstone Inc reported no remaining Context Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Blackstone Inc sold 2,440,330 Context Therapeutics shares in Q1 2026, an estimated $3.59M.
  • Blackstone Inc first reported a position in Context Therapeutics in Q2 2024 and held it in 7 quarters.
  • Blackstone Inc's Context Therapeutics position peaked at $4.78M in Q3 2024.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Blackstone Inc's 13F filing for Q1 2026, filed 15 May 2026.